Compound A and HER2 Inhibitor Combination for PI3K Pathway Shutdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers with overexpressed HER2, such as breast cancer, often require multiple therapies and may not fully inhibit the PI3K pathway, leading to potential resistance and recurrence.
Innovation Solution
The use of Compound A, a dual inhibitor of p70S6K and Akt, in combination with HER2 inhibitors like lapatinib or trastuzumab, to synergistically target cancer cells, offering a more effective shutdown of the PI3K pathway and enhanced anti-tumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for HER2+ cancers are used, then cancer cells are targeted, but the PI3K pathway is not fully inhibited leading to resistance and recurrence
Solution Approach 1:
The patent combines Compound A (which inhibits Akt and p70S6K, two key downstream effectors of the PI3K pathway) with HER2 inhibitors to create a synergistic therapeutic regimen. This combination approach merges multiple mechanisms of action to achieve complete shutdown of the PI3K pathway, preventing resistance and recurrence while treating HER2+ cancers
2Reliability
If multiple therapies are used to treat HER2+ cancers, then anti-tumor activity is enhanced, but treatment complexity increases
Solution Approach 1:
Compound A serves multiple functions simultaneously by inhibiting both Akt and p70S6K, two critical downstream kinases in the PI3K pathway. This multi-functional inhibitor provides broad anti-tumor activity against HER2+ cancers while blocking multiple survival and proliferation signals, thereby enhancing therapeutic efficacy without requiring an excessively complex treatment regimen
Data Source
Figure 1
Figure 2
AI summary
The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3- trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.